-
Notifications
You must be signed in to change notification settings - Fork 0
/
page32_nccn_jsonld.jsonld
166 lines (159 loc) · 5.59 KB
/
page32_nccn_jsonld.jsonld
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
{
"@context": {
"nccn": "http://nccn-guideline.org/vocab#",
"xsd": "http://www.w3.org/2001/XMLSchema#",
"nccn:next": {
"@type": "@id"
},
"nccn:prev": {
"@type": "@id"
},
"nccn:contains": {
"@type":"@id"
},
"nccn:reference": {
"@type":"@id"
}
},
"@graph": [
{
"@id": "http://nccn-guideline.org/vocab/0",
"@type": "nccn:CLINICAL ASSESSMENT",
"nccn:content": "Stage IIIB (T1–2, N3)Stage IIIC (T3, N3)",
"nccn:prev": [],
"nccn:next": [
"http://nccn-guideline.org/vocab/1"
]
},
{
"@id": "http://nccn-guideline.org/vocab/1",
"@type": "nccn:PRETREATMENT EVALUATION",
"nccn:contains": ["http://nccn-guideline.org/vocab/1a","http://nccn-guideline.org/vocab/1b","http://nccn-guideline.org/vocab/1c","http://nccn-guideline.org/vocab/1d"],
"nccn:prev": [
"http://nccn-guideline.org/vocab/0"
],
"nccn:next": ["http://nccn-guideline.org/vocab/2","http://nccn-guideline.org/vocab/3","http://nccn-guideline.org/vocab/4"]
},
{
"@id": "http://nccn-guideline.org/vocab/2",
"@type": "nccn:PRETREATMENT EVALUATION",
"nccn:content": "N3 negative",
"nccn:prev": [
"http://nccn-guideline.org/vocab/1"
],
"nccn:next": ["http://nccn-guideline.org/vocab/5"]
},
{
"@id": "http://nccn-guideline.org/vocab/3",
"@type": "nccn:PRETREATMENT EVALUATION",
"nccn:content": "N3 positive",
"nccn:prev": [
"http://nccn-guideline.org/vocab/1"
],
"nccn:next": ["http://nccn-guideline.org/vocab/6"]
},
{
"@id": "http://nccn-guideline.org/vocab/4",
"@type": "nccn:PRETREATMENT EVALUATION",
"nccn:content": "Metastatic disease",
"nccn:prev": [
"http://nccn-guideline.org/vocab/1"
],
"nccn:next": ["http://nccn-guideline.org/vocab/7"]
},
{
"@id": "http://nccn-guideline.org/vocab/5",
"@type": "nccn:INITIAL TREATMENT",
"nccn:content": "Initial treatment for stage I–IIIA (NSCL-9)",
"nccn:prev": [
"http://nccn-guideline.org/vocab/2"
],
"nccn:next": []
},
{
"@id": "http://nccn-guideline.org/vocab/6",
"@type": "nccn:INITIAL TREATMENT",
"nccn:content": "Definitive concurrent chemoradiation{l},{t} (category 1)",
"nccn:prev": [
"http://nccn-guideline.org/vocab/3"
],
"nccn:next": ["http://nccn-guideline.org/vocab/9"],
"nccn:reference": ["http://nccn-guideline.org/vocab/l","http://nccn-guideline.org/vocab/t"]
},
{
"@id": "http://nccn-guideline.org/vocab/7",
"@type": "nccn:INITIAL TREATMENT",
"nccn:content": "Treatment for Metastasis limited sites (NSCL-14) or distant disease (NSCL-17)",
"nccn:prev": [
"http://nccn-guideline.org/vocab/4"
],
"nccn:next": []
},
{
"@id": "http://nccn-guideline.org/vocab/8",
"@type": "nccn:INITIAL TREATMENT",
"nccn:content": "Surveillance (NSCL-16)",
"nccn:prev": [
"http://nccn-guideline.org/vocab/9"
],
"nccn:next": []
},
{
"@id": "http://nccn-guideline.org/vocab/9",
"@type": "nccn:INITIAL TREATMENT",
"nccn:content": "Durvalumab{t},{u} (category 1)",
"nccn:prev": [
"http://nccn-guideline.org/vocab/6"
],
"nccn:next": ["http://nccn-guideline.org/vocab/8"],
"nccn:reference": ["http://nccn-guideline.org/vocab/t","http://nccn-guideline.org/vocab/u"]
},
{
"@id": "http://nccn-guideline.org/vocab/j",
"@type": "nccn:Footnote",
"nccn:content": "PET/CT performed skull base to knees or whole body. Positive PET/CT scan findings for distant disease need pathologic or other radiologic confirmation. If PET/CT scan is positive in the mediastinum, lymph node status needs pathologic confirmation."
},
{
"@id": "http://nccn-guideline.org/vocab/l",
"@type": "nccn:Footnote",
"nccn:content": "Principles of Radiation Therapy (NSCL-C)."
},
{
"@id": "http://nccn-guideline.org/vocab/o",
"@type": "nccn:Footnote",
"nccn:content": "If MRI is not possible, CT of head with contrast."
},
{
"@id": "http://nccn-guideline.org/vocab/t",
"@type": "nccn:Footnote",
"nccn:content": "Concurrent Chemoradiation Regimens (NSCL-F)."
},
{
"@id": "http://nccn-guideline.org/vocab/u",
"@type": "nccn:Footnote",
"nccn:content": "Durvalumab is not recommended for patients following definitive surgical resection."
},
{
"@id": "http://nccn-guideline.org/vocab/1a",
"@type": "nccn:PRETREATMENT EVALUATION",
"nccn:content": "PFTs (if not previously done)"
},
{
"@id": "http://nccn-guideline.org/vocab/1b",
"@type": "nccn:PRETREATMENT EVALUATION",
"nccn:content": "FDG PET/CT scan{j} (if not previously done)",
"nccn:reference": "http://nccn-guideline.org/vocab/j"
},
{
"@id": "http://nccn-guideline.org/vocab/1c",
"@type": "nccn:PRETREATMENT EVALUATION",
"nccn:content": "Brain MRI with contrast{o}",
"nccn:reference": "http://nccn-guideline.org/vocab/o"
},
{
"@id": "http://nccn-guideline.org/vocab/1d",
"@type": "nccn:PRETREATMENT EVALUATION",
"nccn:content": "Pathologic confirmation of N3 disease by:\u0017Mediastinoscopy\u0017Supraclavicular lymph node biopsy \u0017Thoracoscopy \u0017Needle biopsy \u0017Mediastinotomy \u0017EUS biopsy\u0017EBUS biopsy"
}
]
}